Abstract
Treatment strategies for patients with advanced non-small cell lung cancer (NSCLC) without targetable driver mutations have changed significantly during the last decade. Immune checkpoint inhibitors (ICIs), with or without chemotherapy, have become the first-line (1L) standard of care. Limited clinical data is available to help guide treatment decisions for treatment post-progression. Nintedanib (Vargatef®) is an oral triple angiokinase inhibitor targeting the vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR), and fibroblast growth factor receptor (FGFR) pathways.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
